Scotland carries a disproportionately high burden of Hepatitis C relative to the rest of the UK, with Glasgow's Greater Glasgow and Clyde health board managing one of the highest HCV prevalence rates in Western Europe — driven historically by high rates of injecting drug use. NHS Scotland has made significant progress in its elimination programme, but access gaps remain for patients in recovery who have left structured services or face waiting periods. Resof L provides an affordable cure pathway alongside NHS channels.
The same Ledipasvir+Sofosbuvir combination as brand Harvoni achieves SVR12 cure rates above 95% in Genotype 1 patients — the dominant genotype in Scotland. A full 12-week course through Unnati Pharmax costs a fraction of private UK brand pricing.
Visit medshopy.com or WhatsApp +91 82650 41513.
The same Ledipasvir+Sofosbuvir combination as brand Harvoni achieves SVR12 cure rates above 95% in Genotype 1 patients — the dominant genotype in Scotland. A full 12-week course through Unnati Pharmax costs a fraction of private UK brand pricing.
Visit medshopy.com or WhatsApp +91 82650 41513.
Why does Scotland have such high Hepatitis C rates compared to the rest of the UK?Scotland's historically high HCV prevalence stems from a heroin epidemic that peaked in the 1980s-90s, when needle exchange programmes were less established and injecting drug use spread HCV rapidly through shared equipment in Glasgow, Edinburgh, and other cities. Compounding this was the specific pattern of "poly-drug use" common in Scottish cities, with high rates of injecting among young people in deprived urban areas. Scotland has since become a world leader in harm reduction approaches, but the legacy of that epidemic means the UK's highest HCV burden remains concentrated in Scotland — particularly in Greater Glasgow — making elimination here both more challenging and more urgent.
